top of page

GEN has signed an important partnership and collaboration agreement with Jaguar Health Inc.

GEN has signed an important partnership and collaboration agreement with Jaguar Health Inc.


As a result of the search for new products, new production-sales-distribution relations/regions and new partnerships in linewith our global growth and innovation strategies our company became a partner of Jaguar Health Inc. (NASDAQ: JAGX), which develops innovative drugs and traded on Nasdaq Stock Exchange according to the share purchase agreement signed between. GEN became a shareholder of Jaguar Health Inc. through a capital increase with shares of 6,70%.


Also, a new business relationship has been established between GEN and Jaguar Health Inc. According to the agreement, cooperation has been reached between GEN and Jaguar Health Inc. regarding the Crofelemer, which was developed by Jaguar Health Inc. and has the trade name Mytesi. The agreement is about Crofelemer's US FDA(United States Food and Drug Administration) approved indication of HIV treatment-related diarrhoea and all other indications, including cancer treatment-related diarrhoea, which is in the phase 3 clinical trial stage.

Within the framework of this agreement, GEN will produce finished products containing Crofelemer active substances and will have exclusive sales and marketing rights for all indications mentioned in Türkiye, Belarus, Ukraine, Azerbaijan, Uzbekistan, Kazakhstan, Turkmenistan, Russia, and Georgia.


About Jaguar Health Inc. and Group Companies:


Jaguar Health, Inc. (Jaguar) is a commercial-stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel. Jaguar family company Napo Pharmaceuticals focuses on developing and commercialising human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.


Napo Pharmaceuticals' Crofelemer drug product candidate is the subject of a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy, in 2021, focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged, is focused on developing novel prescription medicines derived from plants for mental health indications.



bottom of page